[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
Article
August 1995

A Topical Carbonic Anhydrase Inhibitor Finally Arrives

Author Affiliations

Miami, Fla

Arch Ophthalmol. 1995;113(8):985-986. doi:10.1001/archopht.1995.01100080035025
Abstract

In this issue of the Archives, Strahlman and associates1 report a 1-year study of the safety profile and efficacy of a topical carbonic anhydrase inhibitor (CAI), dorzolamide hydrochloride (Trusopt), as either primary or supplemental therapy for primary open-angle glaucoma and ocular hypertension. This is the first topical CAI to show sufficient efficacy for clinical use and that appears to nearly match the pressure-lowering of oral CAIs without having their systemic side effects. Having advanced to Food and Drug Administration phase 3 trials, it was approved early this year2 and marketed in June.

The quest to develop a topically active CAI has taken a long time, generating apt comparisons to the biblical 40-year journey in the wilderness needed to reach the promised land. This journey also was circuitous and skeptics wondered if it would be completed.

The rationale for the development of a topically active CAI was to eliminate

×